Prolintane

Prolintane occupies an unusual position as a compound that was once a mainstream prescription stimulant but now exists chiefly as a grey-market research chemical. It was formerly authorized and sold in Europe and elsewhere under brand names such as Villescon and Katovit, often in multivitamin combination products, but it has since been withdrawn from legitimate medical use in essentially all markets. Present-day availability is through online vendors offering it as a not-for-human-consumption research material, outside any medical or regulatory oversight.

Pharmacologically, prolintane acts as a norepinephrine-dopamine reuptake inhibitor of the phenylalkylpyrrolidine family, structurally related to pyrovalerone, and recent laboratory research has further characterized prolintane and synthetic analogues as hybrid ligands at monoamine transporters with notable species differences in their activity at the serotonin transporter. Because it shares mechanistic features with recognized drugs of abuse in the pyrrolidine stimulant class, prolintane carries a meaningful abuse liability, a factor that historically contributed to the curtailment of its medical use.

Despite its former pharmaceutical status, contemporary human safety and dosing data are limited, and much practical information derives from historical use and anecdotal reports rather than modern controlled study. As with other reintroduced stimulants, product purity and dosing accuracy depend on individual suppliers, and the combination of stimulant cardiovascular effects and abuse potential means it should be regarded as a substance requiring considerable caution rather than a benign nootropic.

As a dopaminergic stimulant it can raise heart rate and blood pressure, cause insomnia and anxiety, and invite compulsive redosing during a session. Long or heavy use risks the usual stimulant pattern of sleep loss, appetite suppression, and a rough comedown. Mixing it with other stimulants, MAOIs, or serotonergic drugs raises cardiovascular and serotonergic risk. Not medical advice.

Prolintane is a synthetic central nervous system stimulant of the phenylalkylpyrrolidine class, closely related in structure to pyrovalerone. It was developed in the late 1950s by researchers at Thomae, a division of Boehringer Ingelheim in Germany, with early synthesis routes described in patents filed toward the end of that decade. Boehringer Ingelheim subsequently marketed prolintane in Europe, and it was sold under trade names including Villescon, Promotil, and Katovit, frequently in combination preparations with vitamins. It was prescribed in various countries to counter fatigue and to treat conditions such as asthenia, narcolepsy, and attention disorders. Owing to its stimulant nature and abuse potential, prolintane's medical use declined over subsequent decades, and it was ultimately withdrawn from most markets, with the Spanish product Katovit reportedly discontinued around 2001.

Prolintane is viewed as a functional norepinephrine-dopamine reuptake inhibitor stimulant with a milder and shorter-acting profile than amphetamine, and it is regarded within research chemical circles as a source of increased energy, motivation, and wakefulness. Formerly a legitimate pharmaceutical, it now circulates mainly as a grey-market compound, and user accounts describe useful stimulation for fatigue and productivity alongside typical adverse effects such as insomnia, appetite suppression, and cardiovascular stimulation.

Its recognized abuse liability, which contributed to the decline of its medical use, tempers its reputation, and recent pharmacological work characterizing prolintane and its analogues as hybrid monoamine transporter ligands has renewed modest scientific interest. On balance it is seen as a historically established but now largely obsolete stimulant of moderate potency and non-trivial abuse potential.